PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis early-stage trial tested a drug called adavosertib combined with radiation for people with advanced esophageal or stomach cancer that cannot be removed by surgery. The goal was to find the safest dose and see how well the combination works. Only 4 people took part, so result…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:31 UTC
-
New combo before surgery shows promise against esophageal cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can better control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:29 UTC
-
New combo therapy shows promise in shrinking esophageal tumors before surgery
Disease control OngoingThis study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Cancer-Killing virus joins Chemo-Radiation in fight against esophageal cancer
Disease control OngoingThis early-phase trial tests whether adding a cancer-killing virus (OBP-301) to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The virus is designed to infect and destroy tumor cells. The study e…
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Immunotherapy plus chemoradiation shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis early-phase trial tested a combination of the immunotherapy drug pembrolizumab with chemotherapy and radiation in 16 people whose gastroesophageal cancer could not be removed by surgery. The goal was to see if the treatment could shrink or eliminate the cancer. The study is …
Matched conditions: PATHOLOGIC STAGE IIIA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC